Royalty Pharma Plc (RPRX)
38.09
-0.58
(-1.50%)
USD |
NASDAQ |
Dec 09, 16:00
39.01
+0.92
(+2.42%)
After-Hours: 07:20
Royalty Pharma Cash from Investing (Quarterly): -959.42M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 501.11M |
| Denali Therapeutics, Inc. | 57.83M |
| Amgen, Inc. | -414.00M |
| Eli Lilly & Co. | -2.983B |
| Zenas BioPharma, Inc. | 40.04M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 703.52M |
| Cash from Financing (Quarterly) | 562.94M |
| Free Cash Flow | 1.048B |
| Free Cash Flow Per Share (Quarterly) | -0.4617 |
| Free Cash Flow to Equity (Quarterly) | -1.201B |
| Free Cash Flow to Firm (Quarterly) | -178.79M |
| Free Cash Flow Yield | 4.81% |